On Sept. 20, 2021, Eiger BioPharmaceuticals announced announced that Peginterferon Lambda (Lambda) will be added to the ongoing, multi-center, Phase 3 TOGETHER platform study in outpatients with COVID-19. The primary endpoint is a clinical outcome comparing emergency room visits and/or hospitalization in each active arm versus placebo.